MGNX
MACROGENICS INC
NASDAQ · Healthcare · Biotechnology · US
$2.26
−2.97%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$2.39
From 52W high−53.48%
Volume628423.00
Market cap$144.01M
P/E (TTM)—
P/S (TTM)0.9x
Div yield—
Key dataNov 4, 2026
Open
$2.39
From 52W high
−53.48%
Volume
628423.00
Market cap
$144.01M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
32.7
MomentumView details →
1D Return
−2.97%
YTD Return
+48.14%
SummaryUpdated Jun 1, 2026
MacroGenics, Inc. (NASDAQ:MGNX) is a biopharmaceutical company founded in 2000 and headquartered in Rockville, Maryland. The company went public in October 2013 and specializes in developing and commercializing antibody-based therapeutics for cancer treatment. MacroGenics has successfully brought two FDA-approved medicines to market: MARGENZA for HER2-positive breast cancer and TZIELD for type 1 diabetes prevention. The company operates primarily through its proprietary DART (Dual-Affinity Re-Targeting) platform technology, which enables the creation of novel bispecific antibodies and antibody-drug conjugates (ADCs) designed to enhance immune system targeting of cancer cells.
Similar companies
Latest newsMore news →
MACROGENICS INC appointed Emil Kuriakose as a Class III director and member of its Science and Technology Committee, effective October 30, 2026.21h agoMACROGENICS INC appointed Michael Vasconcelles as a Class II director and member of its Science and Technology Committee, effective October 30, 2026.21h agoMACROGENICS INC announced the appointments of Emil Kuriakose and Michael Vasconcelles.22h ago